Zoeken

236 resultaten voor 'golden coins Visit Buyfc26coins.com for latest FC 26 news 4 13'

Gezocht op "golden coins Visit Buyfc26coins.com for latest FC 26 news 4 13" in plaats van "goldah coins Visit Buyfc26coins.com for latest FC 26 coins news..4Kx3"

Behandeling na (chemo-)immuuntherapie
  • For patients with disease progression after combination ChT and ICI, the recommendations for subsequent treatment are not clear and there is uncertainty
  • found that directly compared docetaxel with best supportive care or other chemotherapy (with or without other treatment) in patients with non-small cell lung
  • New options for combination therapy for advanced non-squamous NSCLC.
  • Welke tweede- en/of derdelijns behandeling bij niet kleincellig longcarcinoom heeft de voorkeur na immuuntherapie en platinum doublet (tegelijkertijd of
  • cancer (NSCLC) without sensitizing oncogene driver mutations after treatment with platinum doublet and (concurrently or consecutive) immunotherapy.
  • als vervolgbehandeling na eerdere behandeling met immuuntherapie en platinum-doublet chemotherapie bij patiënten met een incurabel NSCLC (niet-curatief behandelbaar
  • non-randomized studies) Adverse events: absolute difference <5% for lethal complications, or <25% for serious complications Quality of life: A minimal
  • GOLD studie, glioblastoma: optimizing logistics and dose3. RISinG studie, Re-Irradiation Schedules in Glioma4. PREMIUM, respons predictie melanomen5.
  • Deze werkgroep is ingesteld in het kader van het cluster longoncologie. Werkgroep • dr. A.
  • bij KRAS G12c gemuteerde patiënten (11.3 maanden, 95% CI 9.0-14.9 maanden) (De Langen, 2023) (zie module ‘Behandeling incurabel NSCLC met (zeldzame) mutaties
  • J Clin Epidemiol. 2017 Jul;87:4-13. doi: 10.1016/j.jclinepi.2017.05.006. Epub 2017 May 18. PubMed PMID: 28529184; PubMed Central PMCID: PMC6542664.
Treatment with Physical training
  • disease) and skin rash in DM.
  • by the American College of Sport Medicine, considered gold standard for aerobic exercise to maintain health and fitness.
  • ); Comorbidities preventing resistance training (severe heart/lung disease, uncontrolled hypertension (systolic blood pressure >160 mmHg, diastolic blood
  • the Knowledge Institute of the Federation of Medical Specialists (www.demedischspecialist.nl/ kennisinstituut) and was financed from the Quality Funds for
  • The draft guideline was also submitted for comment to the Vereniging Spierziekten Nederland, the Dutch Artritis Society and Patiëntenfederatie Nederland
  • Sources: Voet (2019) (Alemo Munters, 2013). 1.4 Fatigue, 1.5 (muscle) pain, 1.6 disease activity, 1.7 disease damage No GRADE Because of a lack of data
  • decision making; and muscle strength, disease activity, and disease damage as important outcomes for decision making.
  • Has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of
  • A multidisciplinary working group was set up in 2020 for the development of the guideline module, consisting of representatives of all relevant specialisms
  • Health equity: Reimbursement of physical therapy for neuromuscular diseases falls under the list of chronic diseases (formerly "Chronic list Borst"); physical
  • J Clin Epidemiol. 2017 Jul;87:4-13. doi: 10.1016/j.jclinepi.2017.05.006. Epub 2017 May 18. PubMed PMID: 28529184; PubMed Central PMCID: PMC6542664.
Dubbele immuuntherapie
  • Chemo-immunotherapy is registered as first-line treatment for patients with advanced non-small-cell lung cancer.
  • The 2023 ASCO meeting abstract of the 4-year results reported an OS rate of 23% for the dual immunotherapy plus CT group versus 13% in the CT group for
  • : 160 disease progression 21 study drug toxicity 24 unrelated adverse event 4 withdrew consent 1 died 7 patient request 1 lost to follow-up 3 other Overall
  • Wat is de plaats van dubbele immuuntherapie bij patiënten met stadium IIIB/C/IV NSCLC?
  • Source: Reck, 2023
  • Overweeg bij patiënten met een incurabel NSCLC (niet-curatief behandelbaar stadium III-IV) met tumoren met een PD-L1 van kleiner dan 1% een behandeling
  • Shen (2021) included six RCTs, of which two were not relevant for this literature summary because of the small cell lung cancer population and one was
  • GOLD studie, glioblastoma: optimizing logistics and dose3. RISinG studie, Re-Irradiation Schedules in Glioma4. PREMIUM, respons predictie melanomen5.
  • Deze werkgroep is ingesteld in het kader van het cluster longoncologie. Werkgroep • dr. A.
  • Tabel 1: 4-jaars overleving dubbele versus enkele immuuntherapie plus chemotherapie Studie Referentie Vergelijking 4-year median OS (PD-L1 < 1%) CheckMate
  • J Clin Epidemiol. 2017 Jul;87:4-13. doi: 10.1016/j.jclinepi.2017.05.006. Epub 2017 May 18. PubMed PMID: 28529184; PubMed Central PMCID: PMC6542664.

De richtlijnendatabase is de centrale plek voor evidence based richtlijnen van alle specialismen.

Ontwikkeld door medisch specialisten gelieerd aan de wetenschappelijke verenigingen en het Kennisinstituut van de Federatie Medisch Specialisten.

Meer over richtlijnen